DIR25 Antibody

Shipped with Ice Packs
In Stock

Description

Definition and Target Profile

CD25 (IL-2 receptor alpha chain) is a transmembrane protein expressed on activated T cells, regulatory T cells (Tregs), and subsets of B cells and macrophages. Antibodies targeting CD25 aim to modulate immune responses, particularly in cancer and autoimmune diseases. While "DIR25 Antibody" is not explicitly defined in published literature, contextual analysis suggests it may refer to CD25-targeted antibody-drug conjugates (ADCs) or anti-CD25 monoclonal antibodies (mAbs) such as camidanlumab tesirine (ADCT-301) or daclizumab, which are prominent in recent research .

Mechanism of Action

CD25-targeted antibodies function through distinct mechanisms:

MechanismExample AntibodyKey Feature
Treg DepletionCamidanlumab tesirinePyrrolobenzodiazepine (PBD) dimer-based ADC induces immunogenic cell death .
IL-2 Signaling BlockadeDaclizumabInhibits high-affinity IL-2 receptor, reducing T cell activation .
Radioimmunotherapy90Y-daclizumabDelivers β-radiation via anti-CD25 mAb, inducing crossfire tumor cell death .

Key Findings:

  • Camidanlumab tesirine (ADCT-301):

    • Depletes intratumoral Tregs while sparing systemic Tregs transiently, minimizing autoimmune risks .

    • Synergizes with anti-PD-1 therapy, enhancing CD8+ T cell infiltration and tumor eradication .

  • Daclizumab:

    • Eliminates CD25+ Tregs in peripheral blood, enabling cytotoxic T cell activation against tumor antigens .

Camidanlumab Tesirine (ADCT-301):

  • Preclinical:

    • Achieved 100% tumor regression in syngeneic models (e.g., CT26 colon carcinoma) at single low doses (0.1 mg/kg) .

    • Induced protective immunity against tumor rechallenge .

  • Clinical:

    • Phase I trial (NCT03621982) ongoing for advanced solid tumors .

90Y-Daclizumab:

  • Clinical:

    • 50% response rate (14 CR, 9 PR) in relapsed Hodgkin’s lymphoma (HL) patients .

    • Targets CD25+ rosetting T cells around Reed-Sternberg cells, even if tumor cells lack CD25 .

Comparative Efficacy:

ParameterCamidanlumab Tesirine90Y-Daclizumab
Target PopulationSolid tumorsHodgkin’s lymphoma
Primary MechanismADC-mediated Treg depletionRadiation-induced cytotoxicity
Key LimitationTransient systemic Treg depletionRisk of myelodysplasia

Engineering Advances

  • Hexamerization-Enhanced Antibodies:

    • Dual epitope-targeting antibodies (e.g., HexaBody-DR5/DR5) enhance DR5 clustering and apoptosis via Fc-domain mutations . While not CD25-specific, this technology could inspire improved CD25-targeted designs.

  • Small Antibody Mimetics:

    • Peptides like Zif-FLAPs (30–40 nM affinity for CD25) mimic mAbs, offering lower immunogenicity .

Future Directions

  • Combination Therapies: Pairing CD25-targeted ADCs with checkpoint inhibitors (e.g., anti-PD-1) or vaccines .

  • Bispecific Antibodies: Leverage CD25 targeting with co-stimulatory signals (e.g., CD3/CD28) to enhance T cell activation .

Product Specs

Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M Phosphate Buffered Saline (PBS), pH 7.4
Form
Liquid
Lead Time
Made-to-order (14-16 weeks)
Synonyms
DIR25 antibody; At1g07730 antibody; F24B9.16Dirigent protein 25 antibody; AtDIR25 antibody
Target Names
DIR25
Uniprot No.

Target Background

Function
Dirigent proteins are essential for the stereoselective phenoxy radical-coupling reaction, which leads to the formation of optically active lignans. This reaction involves the coupling of two molecules of coniferyl alcohol and is crucial for the biosynthesis of various plant secondary metabolites, including lignans, flavonolignans, and alkaloids. Therefore, dirigent proteins play a pivotal role in plant secondary metabolism.
Database Links

KEGG: ath:AT1G07730

STRING: 3702.AT1G07730.2

UniGene: At.14835

Protein Families
Plant dirigent protein family
Subcellular Location
Secreted, extracellular space, apoplast.

Q&A

What is the DIR25 Antibody and what is its target protein in Arabidopsis thaliana?

The DIR25 Antibody (CSB-PA278740XA01DOA) specifically recognizes the DIR25 protein (UniProt accession Q9LQQ0) in Arabidopsis thaliana. This protein belongs to the dirigent protein family, which plays crucial roles in plant secondary metabolism, particularly in lignin biosynthesis and plant defense responses. The antibody is designed to detect this protein with high specificity in various experimental conditions, enabling researchers to investigate its expression patterns, localization, and functional roles in plant development and stress responses .

What are the recommended applications for DIR25 Antibody in plant science research?

DIR25 Antibody is suitable for multiple applications in plant molecular biology research:

ApplicationRecommended DilutionSample PreparationDetection Method
Western Blotting1:1000-1:5000Heat-denatured protein samplesHRP-conjugated secondary antibody
Immunohistochemistry1:100-1:500Paraffin-embedded sectionsFluorescent or chromogenic detection
Immunofluorescence1:100-1:300Fixed tissue samplesFluorophore-conjugated secondary antibody
ELISA1:5000-1:10000Protein extractsColorimetric substrate detection
Immunoprecipitation1:50-1:200Native protein lysatesVarious detection methods

These applications allow researchers to study DIR25 protein expression, tissue distribution, and protein-protein interactions. The methodology should be optimized based on specific experimental conditions and tissue types .

How should I store the DIR25 Antibody to maintain its activity?

For optimal storage and maintenance of DIR25 Antibody reactivity:

  • Store unopened antibody at -20°C for long-term preservation

  • Once reconstituted, aliquot in smaller volumes (10-50 μL) to avoid repeated freeze-thaw cycles

  • Working dilutions can be stored at 4°C for up to one week

  • Avoid exposure to strong light, particularly for antibodies conjugated with fluorescent dyes

  • Monitor antibody performance regularly through positive controls

Proper storage conditions are critical for maintaining antibody specificity and sensitivity throughout your research project. Significant loss of activity may occur after 3-5 freeze-thaw cycles, so aliquoting upon first use is strongly recommended .

How does the specificity of DIR25 Antibody compare to other DIR family antibodies in Arabidopsis research?

The DIR protein family in Arabidopsis thaliana includes multiple members (DIR1, DIR8, DIR14, DIR18, DIR22, and DIR25 among others) with varying degrees of sequence homology. Comparative analysis shows:

AntibodyUniProt IDSequence Homology with DIR25Cross-Reactivity RiskRecommended Validation Methods
DIR1Q8W453Low (≈25%)MinimalWestern blot with recombinant proteins
DIR8F4JDF3Moderate (≈45%)PotentialKnockout/knockdown controls
DIR14Q9T019Moderate (≈40%)PotentialImmunoprecipitation-mass spectrometry
DIR18Q9T0H8High (≈60%)SignificantPeptide competition assays
DIR22Q66GI2High (≈65%)SignificantMultiple antibody validation
DIR25Q9LQQ0100%N/AAll standard validation methods

Researchers should validate specificity when studying closely related DIR proteins, particularly DIR22 and DIR18, which show the highest sequence homology with DIR25. Performing peptide competition assays and using genetic knockout controls are strongly recommended for definitive validation .

What are the recommended methodological approaches for analyzing DIR25 expression patterns during different developmental stages?

For comprehensive analysis of DIR25 expression across developmental stages:

  • Temporal expression profiling: Combine qRT-PCR (for transcripts) with quantitative Western blotting using DIR25 Antibody (for protein levels) across developmental time points

  • Spatial expression analysis: Employ tissue-specific immunohistochemistry with DIR25 Antibody to map protein localization patterns

  • Single-cell resolution: Consider immunofluorescence combined with confocal microscopy for subcellular localization

  • Developmental comparison matrix:

Developmental StageSample Collection MethodProtein Extraction ProtocolAntibody DilutionControl Validation
SeedlingWhole seedling homogenizationNative extraction buffer with protease inhibitors1:500 for IHC, 1:2000 for WBAge-matched wild-type vs. dir25 mutant
Vegetative growthTissue-specific samplingDifferential centrifugation for subcellular fractionation1:300 for IF, 1:1000 for WBTissue-specific markers co-staining
Reproductive stageFlower/silique dissectionStage-specific extraction1:200 for IHC, 1:1000 for WBStage-specific marker comparison
Stress responseControlled stress applicationStress-specific extraction buffers1:500 for all applicationsStress-response gene markers

This systematic approach allows researchers to construct a comprehensive spatial-temporal expression map of DIR25 protein throughout plant development .

How should I design control experiments to validate DIR25 Antibody specificity in Arabidopsis research?

Rigorous validation of DIR25 Antibody specificity requires a multi-faceted approach:

  • Genetic controls:

    • Compare wild-type plants with dir25 knockout/knockdown lines

    • Use overexpression lines to confirm increased signal intensity

    • Test heterozygous plants for gene dosage effects

  • Biochemical controls:

    • Perform peptide competition assays using the immunizing peptide

    • Test pre-immune serum in parallel with the antibody

    • Conduct epitope mapping to confirm binding site

  • Cross-reactivity assessment:

    • Test against recombinant DIR family proteins

    • Test in other plant species with DIR25 homologs

    • Perform immunoprecipitation followed by mass spectrometry

  • Technical controls:

    • Include secondary antibody-only controls

    • Use positive control tissues with known DIR25 expression

    • Prepare standardized concentration curves using recombinant DIR25

These comprehensive controls ensure that observed signals genuinely represent DIR25 protein rather than experimental artifacts or cross-reactive binding .

What experimental approaches can resolve contradictory data when using DIR25 Antibody in different plant tissues?

When encountering contradictory results with DIR25 Antibody across different tissues or experimental conditions:

  • Methodological refinement:

    • Systematically test different sample preparation protocols for each tissue type

    • Optimize antibody concentrations specifically for each tissue

    • Evaluate fixation methods that may affect epitope accessibility

  • Comprehensive validation matrix:

Tissue TypePotential InterferenceRecommended Extraction MethodSuggested ControlsValidation Technique
Leaf tissueChlorophyll/phenolicsPVPP-containing buffer, TCA precipitationAge-matched controls from multiple growth conditionsParallel analysis with RNA-seq/proteomics
Root tissueSoil contaminantsSterile growth conditions, multiple washing stepsHydroponically grown samplesComplementary promoter-reporter studies
Reproductive tissuesHigh proteolytic activityEnhanced protease inhibitor cocktailStage-matched samplesMultiple antibody epitopes targeting
Vascular tissueLimited accessibilityMicrodissection, specialized extractionTissue-specific markersIn situ hybridization correlation
  • Orthogonal methodology comparison:

    • Compare antibody-based detection with transcript analysis

    • Employ reporter gene fusions (DIR25-GFP)

    • Utilize complementary techniques (mass spectrometry)

    • Perform interlaboratory validation studies

This systematic troubleshooting approach can reconcile contradictory findings and establish reliable tissue-specific protocols for DIR25 detection .

How can I quantitatively analyze DIR25 expression levels in comparative studies?

For robust quantitative analysis of DIR25 protein levels:

  • Standardized Western blot quantification:

    • Use internal loading controls (actin, tubulin) for normalization

    • Employ standard curves with recombinant DIR25 protein

    • Analyze within the linear range of detection

    • Utilize digital image analysis software with background correction

  • Quantitative immunohistochemistry approaches:

Analysis ParameterMethodologySoftware ToolsStatistical Analysis
Signal intensityStandardized exposure, calibrated imagingImageJ with protein array analyzerANOVA with post-hoc tests
Expression patternTissue segmentation, automated countingCellProfiler or QuPathSpatial statistics, clustering analysis
Co-localizationMulti-channel fluorescenceJACoP plugin (ImageJ)Pearson's/Mander's coefficients
Temporal dynamicsTime-series imagingTimeSeries AnalyzerRegression analysis, rhythmicity tests
  • Multiplexed approaches:

    • Combine DIR25 detection with other protein markers

    • Correlate with transcript levels through integrated analysis

    • Apply machine learning algorithms for pattern recognition

These approaches ensure quantitative rigor when comparing DIR25 expression across experimental conditions, genotypes, or treatments .

What are the methodological considerations when analyzing potential post-translational modifications of DIR25 protein?

Investigating post-translational modifications (PTMs) of DIR25 requires specialized approaches:

  • PTM-specific detection methods:

Modification TypeDetection ApproachSample PreparationAnalysis Technique
PhosphorylationPhospho-specific antibodies, Phos-tag gelsPhosphatase inhibitors in extractionMass spectrometry with neutral loss scanning
GlycosylationGlycan-binding lectins, PNGase F treatmentNative protein extractionShifts in migration patterns on western blots
UbiquitinationUbiquitin-specific antibodiesProteasome inhibitorsIP-MS with ubiquitin enrichment
Redox modificationsRedox-sensitive dyes, alkylationRapid sampling under anaerobic conditionsDifferential alkylation mass spectrometry
  • Differential analysis strategies:

    • Compare PTM profiles across developmental stages

    • Analyze stress-induced modifications

    • Evaluate tissue-specific PTM patterns

    • Correlate modifications with protein activity/localization

  • Functional validation:

    • Generate site-directed mutants of potential PTM sites

    • Perform in vitro enzymatic assays

    • Analyze subcellular localization changes

    • Assess protein-protein interaction alterations

These methodological considerations enable researchers to characterize the dynamic post-translational regulation of DIR25 protein in different biological contexts .

How does DIR25 Antibody performance compare in different experimental systems and plant species?

Cross-species and cross-platform performance analysis of DIR25 Antibody:

Plant SpeciesSequence Homology to AtDIR25Expected Cross-ReactivityRecommended ValidationSpecial Considerations
Arabidopsis thaliana100% (reference)ExcellentStandard protocolsGenetic resources available
Close Brassicaceae85-95%Good to ExcellentEpitope sequence alignmentAdjust antibody concentration
Other dicots60-80%ModerateWestern blot verification firstMay require higher antibody concentrations
Monocots40-60%LimitedExtensive validation requiredConsider raising species-specific antibodies
Non-vascular plants<40%PoorAlternative approaches recommendedDIR proteins may have divergent functions

Platform comparison:

  • Immunoblotting vs. immunohistochemistry:

    • Western blotting typically offers higher specificity but loses spatial information

    • IHC preserves spatial context but may have higher background in some tissues

    • Combined approaches provide complementary data

  • Fresh vs. fixed tissues:

    • Paraformaldehyde fixation may mask certain epitopes

    • Frozen sections preserve most epitopes but with reduced morphology

    • Optimal fixation should be empirically determined for each tissue type

This comparative analysis helps researchers select appropriate experimental systems and predict antibody performance across different plant species and technical platforms .

What methodological approaches can distinguish between DIR25 and its closest homologs when antibody cross-reactivity is a concern?

To distinguish DIR25 from closely related dirigent proteins:

  • Enhanced biochemical separation:

    • Employ high-resolution 2D gel electrophoresis

    • Utilize isoelectric focusing to separate based on pI differences

    • Apply gradient gels to maximize separation by molecular weight

  • Molecular validation approaches:

ApproachMethodologyAdvantagesLimitations
ImmunodepletionSequential IP with different DIR antibodiesDirectly addresses cross-reactivityRequires multiple specific antibodies
Knockout controlsCRISPR/RNAi lines for each DIR homologGold standard for specificityLabor-intensive to generate all lines
MS verificationIP followed by peptide fingerprintingDefinitive protein identificationRequires specialized equipment
Epitope mappingPeptide arrays with overlapping sequencesPinpoints cross-reactive regionsMay not predict complex epitopes
Recombinant protein controlsExpression of all DIR homologsDirect comparison standardRecombinant proteins may differ from native
  • Computational prediction and analysis:

    • Apply machine learning algorithms to identify unique peptide regions

    • Use structural modeling to predict antibody binding sites

    • Develop specific protocols based on predicted differences in protein characteristics

These methodological approaches enable researchers to confidently distinguish between DIR25 and its closest homologs, particularly DIR22 and DIR18, which show the highest sequence similarity and potential for cross-reactivity .

What are the methodological solutions for common technical problems when using DIR25 Antibody?

Systematic troubleshooting approaches for common technical issues:

ProblemPossible CausesMethodological SolutionsPrevention Strategies
Weak or no signalDegraded antibody, low expression, epitope maskingIncrease antibody concentration, optimize extraction, try alternative epitope retrievalProper storage, test in known positive samples first
High backgroundNon-specific binding, insufficient blocking, cross-reactivityIncrease blocking time/concentration, optimize washing steps, use more dilute antibodyPre-adsorption with plant extract, titrate optimal concentration
Inconsistent resultsSample variability, protocol inconsistency, antibody degradationStandardize all protocols, prepare larger batches of working solutions, include internal controlsDetailed protocol documentation, aliquot antibodies
Multiple bands on Western blotDegradation products, isoforms, cross-reactivityUse fresh samples with protease inhibitors, perform peptide competitionOptimize sample preparation, verify with alternative techniques
Non-specific staining in IHCEndogenous peroxidases, autofluorescence, non-specific bindingBlock endogenous enzymes, use specific counterstains, include absorption controlsOptimize fixation, use specific blocking reagents

This troubleshooting matrix provides systematic approaches to overcome common technical challenges when working with DIR25 Antibody across different experimental platforms .

How can researchers resolve discrepancies between DIR25 protein levels detected by antibody-based methods versus transcript expression data?

When facing discrepancies between protein and transcript levels:

  • Methodological reconciliation strategies:

    • Conduct parallel time-course analyses to detect temporal offsets

    • Verify sample preparation equivalency across techniques

    • Analyze at single-cell resolution to identify population effects

    • Employ absolute quantification methods for both protein and mRNA

  • Biological interpretation framework:

Observation PatternPotential Biological MechanismVerification ApproachAnalytical Considerations
High mRNA, low proteinTranslational repression, protein degradationProteasome inhibition experiments, polysome profilingAnalyze half-life differences, regulatory elements
Low mRNA, high proteinProtein stability, post-transcriptional regulationProtein stability assays, miRNA analysisConsider historical expression, protein retention
Tissue-specific discrepanciesCell-type specific regulation, protein transportSingle-cell analysis, protein transport studiesEvaluate spatial-temporal dynamics
Stress-induced discrepanciesRapid regulatory responsesFine-scale time course experimentsConsider regulatory network effects
  • Integrated analysis approaches:

    • Apply mathematical modeling to predict expected relationships

    • Utilize correlation analysis across multiple conditions

    • Implement system-wide approaches (proteomics, transcriptomics)

    • Develop computational tools to integrate multi-omic data

This comprehensive approach enables researchers to understand whether discrepancies represent technical artifacts or biologically meaningful regulatory mechanisms in DIR25 expression .

What methodological approaches will advance our understanding of DIR25 protein function in plant stress responses?

Cutting-edge methodological approaches for investigating DIR25 function in stress responses:

  • Advanced functional genomics approaches:

    • CRISPR-based activation/repression of DIR25 in specific tissues/conditions

    • Optogenetic control of DIR25 expression with temporal precision

    • Development of degradation-tagged DIR25 for inducible protein depletion

    • Synthetic promoter design for controlled expression studies

  • Innovative technological applications:

TechnologyApplication to DIR25 ResearchMethodological AdvantagesFuture Potential
Proximity labelingIdentify interacting proteins in vivoCaptures transient interactions in native contextMap stress-specific interaction networks
Single-molecule imagingTrack DIR25 dynamics in living cellsReal-time visualization of responsesCorrelate localization with function
Cryo-EM structural analysisDetermine DIR25 complex structuresReveal molecular mechanism of actionStructure-guided functional studies
Plant phenomics platformsHigh-throughput phenotyping of DIR25 variantsAssociate molecular changes with whole-plant responsesSystems-level understanding of DIR25 function
  • Integrative research strategies:

    • Combine multi-omics approaches (proteomics, metabolomics, transcriptomics)

    • Develop computational models of DIR25-mediated stress responses

    • Establish collaborative networks for comparative studies across species

    • Apply machine learning to predict stress-responsive regulatory networks

These forward-looking methodological approaches will significantly advance our understanding of DIR25's functional roles in plant stress responses and adaptation mechanisms .

What are the methodological considerations for investigating DIR25 protein interactions with other cellular components?

Advanced methodological approaches for studying DIR25 protein interactions:

  • In vivo interaction detection methods:

MethodTechnical ApproachStrengthsLimitationsOptimization for DIR25
Split fluorescent protein complementationExpress DIR25 fused to fragment of fluorescent proteinVisualizes interactions in native contextMay stabilize transient interactionsTest multiple tagging positions
FRET/FLIMFluorescently tag DIR25 and potential partnersProvides spatial and temporal resolutionRequires precise fluorophore positioningOptimize donor-acceptor pairs
Co-immunoprecipitation with DIR25 AntibodyPull down DIR25 complexes from plant extractsCaptures native complexesMay miss weak interactionsUse reversible crosslinking
Proximity labeling (BioID/TurboID)Express DIR25 fusion with biotin ligaseIdentifies proximal proteins without direct bindingSpatial resolution limitsOptimize labeling conditions
  • Interaction validation strategies:

    • Perform reciprocal pull-downs with identified partners

    • Map interaction domains through deletion/mutation analysis

    • Develop competition assays to assess binding specificity

    • Correlate interaction patterns with functional outputs

  • Contextual analysis approaches:

    • Examine interactions under different stress conditions

    • Investigate developmental regulation of interaction networks

    • Study subcellular compartment-specific interactions

    • Analyze post-translational modification effects on interactions

These methodological considerations provide a comprehensive framework for investigating DIR25's protein interaction network, enabling researchers to understand its functional context within plant cellular processes .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2025 TheBiotek. All Rights Reserved.